In particular, PMOs conjugated to arginine-rich CPPs (known as P-PMOs) have been shown to enhance dystrophin production in muscle following systemic administration in the mdx mouse model of DMD (14–16). Here, DMD is linked to Duchenne muscular dystrophy.